Abstract
Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67
Original language | Undefined/Unknown |
---|---|
Pages (from-to) | 43-51 |
Number of pages | 9 |
Journal | European Journal of Cancer |
Volume | 136 |
DOIs | |
Publication status | Published - Sep 1 2020 |
Keywords
- Adult
- Aged
- 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- administration & dosage
- adverse effects
- pharmacology
- Breast Neoplasms
- diagnosis
- drug therapy
- mortality
- pathology
- Chemotherapy
- Adjuvant
- Cohort Studies
- Disease Progression
- Dose-Response Relationship
- Drug
- Female
- Humans
- Immunohistochemistry
- Middle Aged
- Neoplasm Staging
- Phenotype
- Prognosis
- Receptor
- ErbB-2
- metabolism
- Receptors
- Estrogen
- Progesterone
- Survival Analysis
- Breast cancer
- Dose-dense chemotherapy
- Hormone receptor-positive
- Luminal subtype